Cardlytics, Inc. (NASDAQ:CDLX) Insider Nicholas Hollmeyer Lynton Sells 5,936 Shares

Cardlytics, Inc. (NASDAQ:CDLXGet Free Report) insider Nicholas Hollmeyer Lynton sold 5,936 shares of the firm’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $3.08, for a total transaction of $18,282.88. Following the completion of the sale, the insider now directly owns 85,445 shares in the company, valued at $263,170.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Cardlytics Trading Down 1.3 %

NASDAQ CDLX opened at $3.07 on Thursday. The company’s fifty day simple moving average is $4.56 and its 200-day simple moving average is $8.59. Cardlytics, Inc. has a 52 week low of $2.89 and a 52 week high of $20.52. The company has a current ratio of 1.77, a quick ratio of 1.77 and a debt-to-equity ratio of 1.01. The stock has a market cap of $149.76 million, a P/E ratio of -0.69 and a beta of 1.68.

Cardlytics (NASDAQ:CDLXGet Free Report) last posted its earnings results on Wednesday, August 7th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.12. Cardlytics had a negative net margin of 50.21% and a negative return on equity of 17.96%. The business had revenue of $69.64 million for the quarter, compared to analysts’ expectations of $75.39 million. During the same period in the previous year, the company posted ($0.57) earnings per share. The business’s revenue for the quarter was down 9.2% compared to the same quarter last year. Equities research analysts predict that Cardlytics, Inc. will post -1.72 EPS for the current fiscal year.

Institutional Trading of Cardlytics

A number of hedge funds and other institutional investors have recently made changes to their positions in CDLX. Renaissance Technologies LLC increased its stake in shares of Cardlytics by 711.9% in the second quarter. Renaissance Technologies LLC now owns 351,035 shares of the company’s stock worth $2,882,000 after buying an additional 307,800 shares during the last quarter. Kent Lake Capital LLC bought a new stake in shares of Cardlytics in the first quarter worth $3,622,000. Perbak Capital Partners LLP bought a new stake in shares of Cardlytics in the first quarter worth $2,348,000. General Equity Holdings LP increased its stake in Cardlytics by 31.0% during the fourth quarter. General Equity Holdings LP now owns 624,058 shares of the company’s stock valued at $5,748,000 after purchasing an additional 147,843 shares during the last quarter. Finally, Blackstone Inc. bought a new stake in Cardlytics during the first quarter valued at $2,029,000. Institutional investors own 68.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Needham & Company LLC cut shares of Cardlytics from a “buy” rating to a “hold” rating in a research report on Thursday, August 8th. Northland Securities cut shares of Cardlytics from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $7.00 to $5.00 in a research report on Friday, August 16th. Bank of America cut shares of Cardlytics from a “neutral” rating to an “underperform” rating and reduced their price target for the company from $4.00 to $3.50 in a research report on Thursday, August 15th. Northland Capmk cut shares of Cardlytics from a “strong-buy” rating to a “hold” rating in a research report on Friday, August 16th. Finally, Lake Street Capital cut shares of Cardlytics from a “buy” rating to a “hold” rating and reduced their price target for the company from $18.00 to $5.00 in a research report on Thursday, August 8th. One analyst has rated the stock with a sell rating and five have assigned a hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $7.50.

Get Our Latest Stock Report on CDLX

Cardlytics Company Profile

(Get Free Report)

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.

Featured Stories

Insider Buying and Selling by Quarter for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.